跳至主要内容
临床试验/CTRI/2013/10/004041
CTRI/2013/10/004041
尚未招募
未知

Cyberknife® partial breast irradiation for early stage breast cancer

Medanta the Medicity0 个研究点目标入组 24 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Health Condition 1: null- Patients of early stage Carcinoma Breast - post op
发起方
Medanta the Medicity
入组人数
24
状态
尚未招募
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
4年前
研究类型
Interventional

研究者

入排标准

入选标准

  • Eligible patients must have appropriate staging studies identifying them as AJCC stage T1 or T2 less than 3 cm treated with lumpectomy and axillary node dissection with at least 6 nodes sampled or sentinel node biopsy. Patients should be node negative.
  • DCIS or invasive ductal or medullary or papillary or mucinous (colloid)or or tubular histologies.
  • The patients Karnofsky performance status (KPS) must be more than 80percent
  • Patients must be more or equal to 40 years of age.
  • If chemotherapy is planned it must begin no earlier than two weeks following completion of radiation therapy.
  • Unifocal breast cancer (no evidence of gross multifocal disease or multicentric or bilateral disease confirmed on preoperative breast MRI).
  • Negative margins after lumpectomy (re\-excision for initial positive margins is allowed\-negative margins defined as more than 2 mm clear of tumor in all directions).
  • Negative post\- lumpectomy mammography if malignancy\-associated microcalcifications were initially present.
  • The target lumpectomy cavity must be clearly delineated.
  • Patients must complete appropriate pretreatment evaluation including post\-lumpectomy mammogram if microcalcifications were initially present to confirm complete removal.

排除标准

  • Evidence of suspicious microcalcifications in the breast prior to start of radiation.
  • Patients with history of collagen vascular disease specifically dermatomyositis with a CPK level above normal or active skin rash or systemic lupus erythematosis or scleroderma.
  • Patients with histologically positive axillary nodes.
  • Patients with distant metastases.
  • Patients with invasive or extensive insitu lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.
  • Patients with multicentric gross disease defined as tumors in different quadrants of the breast or tumor separated by at least 4 cm or other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy or biopsy.
  • Patients must not have any palpable or radiographically suspicious ipsilateral or contralateral axillary or supraclavicular or infraclavicular or internal mammary nodes unless there is histologic confirmation that these nodes are negative for tumor.
  • Any previously treated contra lateral invasive breast carcinoma or synchronous contra lateral breast carcinoma.
  • Prior non\-hormonal therapy or radiation therapy for the current breast cancer or hormonal therapy for more than 28 days after diagnosis or refusal to discontinue hormonal therapy.
  • Patients with Pagets disease of the nipple.

结局指标

主要结局

未指定

相似试验